Given the clear evidence of positive impact on glycemia, weight, and organ protection, GLP-1 receptor agonists are uniformly recommended by major professional society guidelines to improve outcomes for patients with diabetes and other CKM conditions [23,24,25,26,27,28,29]. Here, GLP1R is linked to diabetes mellitus.